Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.79 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | APLNR | P35414 | 1/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.73 |
| ▸ | GLP1R | P43220 | 1/20 | 0.73 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.73 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.73 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21132895 | 1.00 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL26928891 | 1.00 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL29707992 | 1.00 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL31110348 | 1.00 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL2703475 | 0.94 | GNRHR (0.75) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL20547884 | 0.93 | GNRHR (0.86) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL20547883 | 0.93 | GNRHR (0.86) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL28414319 | 0.93 | GNRHR (0.68) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL28414317 | 0.93 | GNRHR (0.68) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL28418497 | 0.92 | GNRHR (0.75) | GNRHRCYP3A4ADRB2APLNROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425685-A | Synthesis method of oxaagoli sodium impurity | 安徽联创生物医药股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | MOEHS IBERICA, S.L. (ES) | 2024-01-02 | — | — | US | disclosed |
| CN-116425685-A | Synthesis method of oxaagoli sodium impurity | 安徽联创生物医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11542239-B2 | Elagolix sodium compositions and processes | ABBVIE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220242831-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2022-08-04 | — | — | US | disclosed |
| US-11377426-B2 | Processes to produce elagolix | SUZHOU PENGXU PHARMATECH CO., LTD. (CN) | 2022-07-05 | — | — | US | disclosed |
| US-20210214318-A1 | PROCESSES TO PRODUCE ELAGOLIX | SUZHOU PENGXU PHARMATECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| WO-2021064561-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX SODIUM | NEULAND LABORATORIES LIMITED (IN) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021009034-A1 | 3-[2(R)-AMINO-2-PHENYLETHYL]-5-(2-FLUORO-3-METHOXYPHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]-6-METHYL-1H-PYRIMIDINE-2,4(1H,3H)-DIONE HYDROCHLORIDE SALT (I) IN SOLID FORM, PROCESS FOR PREPARING SAME, AND USE THEREOF IN THE SYNTHESIS OF ELAGOLIX | MOEHS IBERICA, S.L. (ES) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020240375-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | DR. REDDY’S LABORATORIES LIMITED (IN) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020194115-A1 | PROCESS FOR THE PREPARATION OF ELAGOLIX SODIUM AND INTERMEDIATES THEREOF | MANKIND PHARMA LTD. (IN) | 2020-10-01 | — | — | WO | disclosed |
| US-20200138819-A1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| WO-2019115019-A1 | PROCESS FOR PREPARING ELAGOLIX | SYNTHON B.V. (NL) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019112968-A1 | PROCESSES TO PRODUCE ELAGOLIX | WANG PENG (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542239-B2 | Elagolix sodium compositions and processes | ELOVL5, ELOC, ELOVL3 | GNRHR 2722/4885CYP3A4 2754/4885ADRB2 2800/4885 |
| US-20200138819-A1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | GNRHR, FSHR, LHCGR | GNRHR 1/4885CYP3A4 2733/4885ADRB2 612/4885 |
| US-20210214318-A1 | PROCESSES TO PRODUCE ELAGOLIX | ELAVL1, ELOB, ELOVL3 | GNRHR 2201/4885CYP3A4 1948/4885ADRB2 4369/4885 |
| US-20220242831-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | PCSK9, XPO5, HAX1 | GNRHR 1142/4885CYP3A4 836/4885ADRB2 3452/4885 |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | JAK2, EML4, AZI2 | GNRHR 4166/4885CYP3A4 3862/4885ADRB2 1306/4885 |
| US-11377426-B2 | Processes to produce elagolix | ELAVL1, ELOB, ELOVL3 | GNRHR 2201/4885CYP3A4 1948/4885ADRB2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.